Health Trials

About this trial

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

Eligibility criteria

Qualifiers

Eligible participants are 10-21 years of age

Have received a heart transplant and are followed participating pediatric heart transplant centers

English-speaking or Spanish-speaking

Own a smart-phone or have access to the mobile app through other devices

Disqualifiers

None

Trial design

Treatments tested in this trial

  • DOT intervention

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

4
University of Miami, Miller School of Medicine33146, Coral GablesFlorida, United States
University of Florida32610, GainesvilleFlorida, United States
Joe DiMaggio Children's Hospital33021, HollywoodFlorida, United States
FSU College of Medicine32306, TallahasseeFlorida, United States

Sponsors and collaborators

University of Florida

Lead sponsor

emocha Mobile Health, Inc.

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Source ClinicalTrials.gov